Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Stereotaxis, Inc.

STXSAMEX
Healthcare
Medical - Instruments & Supplies
$1.91
$0.02(1.06%)
U.S. Market opens in 15h 29m

Stereotaxis, Inc. Fundamental Analysis

Stereotaxis, Inc. (STXS) shows weak financial fundamentals with a PE ratio of -8.31, profit margin of -66.85%, and ROE of -1.92%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.55%.

Key Strengths

PEG Ratio-0.78
Current Ratio1.51

Areas of Concern

ROE-1.92%
Operating Margin-68.30%
We analyze STXS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -216.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-216.7/100

We analyze STXS's fundamental strength across five key dimensions:

Efficiency Score

Weak

STXS struggles to generate sufficient returns from assets.

ROA > 10%
-41.42%

Valuation Score

Excellent

STXS trades at attractive valuation levels.

PE < 25
-8.31
PEG Ratio < 2
-0.78

Growth Score

Weak

STXS faces weak or negative growth trends.

Revenue Growth > 5%
0.55%
EPS Growth > 10%
-11.11%

Financial Health Score

Excellent

STXS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.29
Current Ratio > 1
1.51

Profitability Score

Weak

STXS struggles to sustain strong margins.

ROE > 15%
-191.60%
Net Margin ≥ 15%
-66.85%
Positive Free Cash Flow
No

Key Financial Metrics

Is STXS Expensive or Cheap?

P/E Ratio

STXS trades at -8.31 times earnings. This suggests potential undervaluation.

-8.31

PEG Ratio

When adjusting for growth, STXS's PEG of -0.78 indicates potential undervaluation.

-0.78

Price to Book

The market values Stereotaxis, Inc. at 9.61 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

9.61

EV/EBITDA

Enterprise value stands at -8.84 times EBITDA. This is generally considered low.

-8.84

How Well Does STXS Make Money?

Net Profit Margin

For every $100 in sales, Stereotaxis, Inc. keeps $-66.85 as profit after all expenses.

-66.85%

Operating Margin

Core operations generate -68.30 in profit for every $100 in revenue, before interest and taxes.

-68.30%

ROE

Management delivers $-1.92 in profit for every $100 of shareholder equity.

-1.92%

ROA

Stereotaxis, Inc. generates $-41.42 in profit for every $100 in assets, demonstrating efficient asset deployment.

-41.42%

Following the Money - Real Cash Generation

Operating Cash Flow

Stereotaxis, Inc. generates limited operating cash flow of $-13.31M, signaling weaker underlying cash strength.

$-13.31M

Free Cash Flow

Stereotaxis, Inc. generates weak or negative free cash flow of $-13.40M, restricting financial flexibility.

$-13.40M

FCF Per Share

Each share generates $-0.14 in free cash annually.

$-0.14

FCF Yield

STXS converts -7.69% of its market value into free cash.

-7.69%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-8.31

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.78

vs 25 benchmark

P/B Ratio

Price to book value ratio

9.61

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.40

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.29

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.51

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.92

vs 25 benchmark

ROA

Return on assets percentage

-0.41

vs 25 benchmark

ROCE

Return on capital employed

-0.74

vs 25 benchmark

How STXS Stacks Against Its Sector Peers

MetricSTXS ValueSector AveragePerformance
P/E Ratio-8.3128.25 Better (Cheaper)
ROE-191.60%780.00% Weak
Net Margin-66.85%-20122.00% (disorted) Weak
Debt/Equity0.290.30 Neutral
Current Ratio1.514.66 Neutral
ROA-41.42%-14687.00% (disorted) Weak

STXS outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Stereotaxis, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-31.06%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-287.64%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-36.23%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ